The FDA is looking into reports of potential side effects such as hair loss, aspiration, and suicidal thoughts associated with popular diabetes and weight loss drugs, Ozempic, Wegovy, Mounjaro, and Zepbound. These GLP-1 receptor agonists are used to treat diabetes and weight management. An investigation by the FDA does not mean they have concluded a risk exists but just that they have identified potential safety concerns. The FDA monitors drug safety even after approval and may update labels or implement a risk management plan. There are also international concerns about these drugs. The drug manufacturers stated that patient safety is a priority and they are collaborating with the FDA on these safety concerns.
Source link
FDA Evaluating 3 Side Effects Reported for Weight Loss Drugs
